Author:
Maiara Ferreira Barreto Pires Bruna,Marcia Peres Ellen,Marcos Tosoli Gomes Antonio,Valéria Dantas de Oliveira Souza Norma,Guitton Renaud Baptista de Oliveira Beatriz,Cristina da Silva Thiengo de Andrade Priscila,Mayerhofer Kubota Thais,Faria Cristiene,Carvalho Leite Dayana,Conceição das Merces Magno,Ferreira de Almeida Luana,Sant'anna Nunes Alessandra,Cabral Pereira da Costa Carolina,Fajin de Mello Lívia,Guimarães Assad Luciana,Maria de Sá Basílio Lins Silvia,Pires Silva Rafael,Paula Oliveira Motta Ana,Bertolossi Marta Cristiano,Galdino de Paula Vanessa,de Souza Ramos Raquel,Cupello Peixoto Mauricio,Oliveira Duarte Martins Mônica,de Aguiar Ciríaco Alexandrina,Britto Ribeiro de Jesus Patrícia,da Silva Pires Ariane,Perez Fuentes Junior Eugênio,Ferraz Gomes Helena
Reference23 articles.
1. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): Considerations for clinical trial design;Barone;Transfusion,2020
2. Convalescent plasma: A possible treatment of COVID-19 in India;da Silva;Medical Journal, Armed Forces India,2020
3. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: A systematic review and meta-analysis;Devasenapathy;CMAJ,2020
4. Effectiveness of convalescent plasma therapy in severe COVID-19 patients;Duan;Proceedings of the National Academy of Sciences,2020
5. Food and Drug Administration. Investigational-covid-19-convalescent-plasma-emergency-inds. US Food and Drug Administration. USA: Food and Drug Administration; 2020 [cited Jul 8 2020]. Available from: https://www.fda.gov/vaccines-bloodbiologics/investigational-new-drug-ind-or-device-exemption-ide-processcber/investigational-covid-19-convalescent-plasma-emergency-inds.